Research ArticleExperimental Studies

Effect of pO2 on Antitumor Drug Cytotoxicity on MDR and Non-MDR Variants Selected from the LoVo Metastatic Colon Carcinoma Cell Line

ISABELLE LELONG-REBEL, CHRISTINE BRISSON, MICHEL FABRE, JEAN-PIERRE BERGERAT and GÉRARD REBEL
Anticancer Research January 2008, 28 (1A) 55-68;

Article Information

vol. 28 no. 1A 55-68
PubMed 
18383825
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received September 24, 2007
  • Revision received November 15, 2007
  • Accepted November 30, 2007
  • Published online January 1, 2008.
Copyright & Usage 
Copyright© 2008 International Institute of Anticaner Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. ISABELLE LELONG-REBEL1,
  2. CHRISTINE BRISSON2,
  3. MICHEL FABRE3,
  4. JEAN-PIERRE BERGERAT1 and
  5. GÉRARD REBEL1
  1. 1EA/ULP 3430, Laboratoire de Cancérologie Expérimentale et de Radiobiologie, IRCAD/HUS, BP426, F-67091 Strasbourg cedex
  2. 2U 433 INSERM, Faculté de Médecine Laennec, F-69372 Lyon, cedex 08
  3. 3Institut d'Histologie, Faculté de Médecine, Université Louis Pasteur, F-67000-Strasbourg, France
  1. Correspondence to: Dr. Isabelle Lelong-Rebel, EA/ULP 3430, Laboratoire de Cancérologie Expérimentale et de Radiobiologie, IRCAD/HUS, 1 Place de l'Hôpital, BP426, F-67091 Strasbourg cedex, France. Tel: +33 3 88 11 90 14, Fax: +33 3 88 11 90 99, e-mail: Isabelle.Lelong{at}ircad.u-strasbg.fr

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Effect of pO2 on Antitumor Drug Cytotoxicity on MDR and Non-MDR Variants Selected from the LoVo Metastatic Colon Carcinoma Cell Line
ISABELLE LELONG-REBEL, CHRISTINE BRISSON, MICHEL FABRE, JEAN-PIERRE BERGERAT, GÉRARD REBEL
Anticancer Research Jan 2008, 28 (1A) 55-68;
Twitter logo Facebook logo Mendeley logo

Jump to section